The FDA has issued warning letters to multiple companies marketing compounded Retatrutide, an investigational drug from Eli Lilly still in Phase II trials. While early studies have shown promising weight loss results, Retatrutide FDA Sends 30 Warning Letters To Continue Clampdown on Compounded GLP 1s BioSpace RX South DBA RX3 Compounding Pharmacy LLC 10 23 14 BPC 157: Miracle Healing Peptide or Hidden Danger? FDA Puts BPC 157, TB 500, and 5 Other Peptides Under the Microscope: What Prescribers Need to Know About the 503A Review Lengea FDA takes first step in possible reversal of ban on some peptides The Washington Post